The standardization therapeutics of ischemic stroke the clinical analysis of 312 patients with stoke
Objective: To study the outcome after the standardization therapeutics of ischemic stroke and the relatively factors which can influence the outcome of patients with stroke. Methods: Using data collected from 312 patients enrolled in the clinical standardization therapeutics trial, and neurological impairment at the hospitalization and the discharge was quantified using the China Stroke Scale (CSS), the outcome at the discharge using the percentage of CSS decreasing. The outcome was rated as cure if the percentage of CSS decreasing was over 89% and dead. Analyses were adjusted for age, history of previous disorders, and the form of onset, blood pressure at onset, complication. Results: The percentage of cure after the thrombolysis was 12.5%, after anticoagulant was 8.23%, after decreasing fibrinogen was 8.57% and after the convention treatment was only 5.66%. And at the same time, the percentage of dead after the thrombolysis was 12.5%, after anticoagulant was 8.23%, after decreasing fibrinogen was 8.57% and after the convention treatment was 10.1%. The other factors had no differently between the variability treatments. The complication could influence the outcome of stroke patients, especially the infect of respiratory, disturbance of kidney and electrolyte. Conclusions: The standardization therapeutics should be contributing the outcome of patients with ischemic stroke.
clinical analysis、ischemic stroke、form of
8
R3 ;R77
2005-07-07（万方平台首次上网日期，不代表论文的发表时间）
共1页
67
